Public Employees Retirement System of Ohio Invests $3.46 Million in BioMarin Pharmaceutical Inc. $BMRN

Public Employees Retirement System of Ohio purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, Holdings Channel reports. The firm purchased 60,483 shares of the biotechnology company’s stock, valued at approximately $3,461,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Primecap Management Co. CA acquired a new position in BioMarin Pharmaceutical in the second quarter worth $811,962,000. Viking Global Investors LP raised its holdings in shares of BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares during the period. Norges Bank bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth about $447,572,000. AQR Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical by 12.7% in the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock worth $395,197,000 after buying an additional 754,807 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of BioMarin Pharmaceutical by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after buying an additional 481,176 shares during the period. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Up 0.2%

BMRN stock opened at $66.53 on Friday. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The firm’s 50-day simple moving average is $62.58 and its 200 day simple moving average is $58.37. The stock has a market cap of $12.88 billion, a PE ratio of 179.81, a price-to-earnings-growth ratio of 0.48 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same period last year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several research reports. HC Wainwright increased their price objective on shares of BioMarin Pharmaceutical from $59.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Barclays lifted their target price on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. BMO Capital Markets began coverage on BioMarin Pharmaceutical in a report on Wednesday, August 19th. They set an “outperform” rating and a $98.00 target price for the company. Oppenheimer increased their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Finally, Morgan Stanley raised their price target on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.17.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.